Less than one in 10 patients that would benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
Per forecasts, more than two billion will be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key obstacles to broad availability to the injections that can assist patients in reducing considerable body mass, explains the agency.
Skinny Jab Shortage
Despite the current most favorable outlook, the production of such drugs might only reach approximately 100 million people – less than 10% of those who need them, according to the WHO.
The advice encourages governments and firms to widen availability, through measures like licensing agreements.
Exclusive production rights on a key compound – the primary component of the drug Wegovy – is set to lapse in a number of countries in 2026.
How Obesity Jabs Work
These medications mimick a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so individuals reduce food intake.
Patients usually see weight reduction within a few weeks of commencing the once-weekly jabs.
Evidence suggests people may put most of the weight back on after a year of halting the drug, because their typical appetite come back.
Being carrying excess weight increases your risk for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
